DealsMay 27, 2026, 08:06 AM
HCW Biologics Regains Full Rights to HCW9201 & HCW9206 from Wugen
AI Summary
HCW Biologics Inc. announced it has exercised its option to terminate the exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to its molecules HCW9201 and HCW9206. This strategic move allows HCW Biologics to regain full commercial rights to these two compounds at no cost, while retaining the initial license fee and 2.2 million shares of Wugen common stock. The company aims to commercialize these reagents, which have shown potential to improve CAR-T cell therapy manufacturing and efficacy, through new partnerships in the fast-growing CAR-T immunotherapy market.
Key Highlights
- HCW Biologics terminated its exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206.
- The company regained full commercial rights to HCW9201 and HCW9206 at no cost, retaining the upfront license fee and 2.2 million Wugen shares.
- The termination was exercised under a 12-month suspension letter agreement from May 30, 2025.
- HCW Biologics plans to commercialize these reagents through corporate partners focused on CAR-T and NK-cell therapies.
- Recent data suggests HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies by enriching for long-lived T-memory stem cells.
- HCW9206 is a novel multi-cytokine fusion protein reagent with potential to enhance CAR-T manufacturing processes.
Price Impact
More from HCWB